Categories: News

Genflow Biosciences PLC Announces Holding(s) in Company – 2

TR-1: Standard form for notification of major holdings

LONDON, UNITED KINGDOM / ACCESSWIRE / January 13, 2025 /

1. Issuer Details

ISIN

GB00BP2C3V08

GENFLOW BIOSCIENCES PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

3. Details of person subject to the notification obligation

Name

Jonathan Mark Swann

City of registered office (if applicable)

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

10-Jan-2025

6. Date on which Issuer notified

13-Jan-2025

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

6.010000

0.000000

6.010000

21025000

Position of previous notification (if applicable)

5.030000

0.000000

5.030000

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

GB00BP2C3V08

21025000

0

6.010000

0.000000

Sub Total 8.A

21025000

6.010000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

none

12. Date of Completion

13-Jan-2025

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com .
SOURCE: Genflow Biosciences PLC

View the original press release on accesswire.com

Staff

Recent Posts

After Trump’s Marijuana Executive Order, Will the DEA Face a Court Imposed Deadline from MMJ’s Writ of Mandamus?

After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…

4 hours ago

Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings

Boards and executive buyers are raising the 2026 bar for all product and service rankings…

7 hours ago

Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings

Boards and executive buyers are raising the 2026 bar for all product and service rankings…

7 hours ago

Awake Breast Augmentation: Gruber Plastic Surgery Highlights Live Implant Sizing Under Local Anesthesia With No Sedation for Eligible Patients

Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…

10 hours ago

Clemson University and Nordic Wellness Launch Groundbreaking Partnership to Transform the Student Mental Health Crisis

Clemson University and Nordic Wellness have launched a pioneering partnership tackling the student mental health…

10 hours ago